Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Propulsid Revised Labeling Reserves Drug For Second-Line Use In GERD

Executive Summary

Janssen's Propulsid (cisapride) should be reserved for second-line use, revised labeling recommends following additional reports of cardiac events and deaths associated with the drug for nocturnal heartburn caused by gastroesophageal reflux disease.

You may also be interested in...

Propulsid Physician Education On Cardiac Risk To Be Presented To Committee

Janssen will detail professional education campaign plans for conveying cardiac risks associated with the nighttime heartburn treatment Propulsid (cisapride) at the April 12 FDA advisory committee review of the product's safety.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts